NCT06675357RecruitingPhase 2
Using FAPI PET/MRI to Evaluate Prostate Cancer
Novel FAP-targeted Approach to Imaging Patients With or High-risk for Metastatic Prostate Cancer
Source: ClinicalTrials.gov · Last updated 10 Jun 2026
Brief summary (registry, in English)
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 4 Nov 2024
- Start date
- 27 Feb 2026
- Primary completion date
- Jan 2027
- Lead sponsor
- University of Wisconsin, Madison
- Diseases
- Prostate cancer
- NCT number
- NCT06675357
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 27 Feb 2026 to the primary completion date, Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have their own prescription for the medication
- The informed consent process is conducted prior to the self-administration of this medication
Other
- Unable or unwilling to provide informed consent
- Contraindication(s) to or inability to undergo PET/MRI
- Participants for whom PET/MRI will delay timely delivery of treatment
- Participants requiring intravenous (IV) conscious sedation for imaging care; those requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:
- Come to the research visit with a driver
Who the study is looking for
- Age 18 years or older
- Able and willing to provide informed consent
- Known diagnosis of prostate cancer
- Scheduled for or recently performed (within 4 weeks) standard-of-care PSMA PET
- Optional: Scheduled for SOC biopsy of an established or suspected non-osseous, non-nodal metastases.
- Willing and able to undergo PET/MRI as part of this research
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Wisconsin Coordinator of this site? Confirm its status | Madison | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.